Compare SGMT & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SGMT | BCIC |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 162.3M |
| IPO Year | 2021 | N/A |
| Metric | SGMT | BCIC |
|---|---|---|
| Price | $4.90 | $7.33 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $26.38 | $9.00 |
| AVG Volume (30 Days) | ★ 321.0K | 156.7K |
| Earning Date | 03-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 15.15% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | $5.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $7.11 |
| 52 Week High | $11.41 | $13.50 |
| Indicator | SGMT | BCIC |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 20.64 |
| Support Level | N/A | N/A |
| Resistance Level | $6.62 | $12.33 |
| Average True Range (ATR) | 0.29 | 0.35 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 25.74 | 8.99 |
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.